Shares of Aeterna Zentaris (AEZS) crater - down 63.1% premarket - after Keryx announces a...

|By:, SA News Editor

Shares of Aeterna Zentaris (AEZS) crater - down 63.1% premarket - after Keryx announces a failure of its perifosince drug to meet endpoints in a Phase 3 clinical trial conducted at 65 U.S. sites. Aetenera Zentaris has a license agreement with Keryx over the drug.